# US 2021/0330788 A1 · Uses of anti-bcma chimeric antigen receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330788 A1
- Document ID: US20210330788A1
- Status: Published application
- Kind: A1
- Application number: 17/258,971
- Filed: 2019-07-10
- Published: 2021-10-28
- Earliest claimed: 2018-07-11
- Assignees: Celgene Corporation
- Applicants: Celgene Corporation
- Inventors: Kristen HEGE; Payal PATEL; Steven NOVICK; Lars STERNAS
- Web page: https://patentgrep.com/patent/US20210330788A1

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 39/39541: {against normal tissues, cells}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4215: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
- A61P 35/00: Antineoplastic agents
- C12N 5/0636: {T lymphocytes}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2039/6006: {Cells}
- A61K 2039/804: {Blood cells [leukemia, lymphoma]}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides uses of anti-B cell maturation antigen (BCMA) chimeric antigen receptors (CARs) for treating B-cell related conditions, such as BCMA-expressing cancers.

## Claims

### Claim 1

A method of depleting BCMA-expressing cells in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of immune cells expressing a chimeric antigen receptor (CAR) directed to B Cell Maturation Antigen (BCMA), wherein the immune cells are administered in a dosage of from 150×106 cells to 450×106 cells, and wherein before said administration said subject has received one or more lines of prior therapy comprising one or more of: a proteasome inhibitor, lenalidomide, pomalidomide, thalidomide, bortezomib, dexamethasone, cyclophosphamide, doxorubicin, carfilzomib, ixazomib, cisplatin, doxorubicin, etoposide, an anti-CD38 antibody, panobinostat, and elotuzumab.

### Claim 2

A method of treating a disease caused by BCMA-expressing cells in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of immune cells expressing a chimeric antigen receptor (CAR) directed to B Cell Maturation Antigen (BCMA), wherein the immune cells are administered in a dosage of from 150×106 cells to 450×106 cells, and wherein before said administration said subject has received one or more lines of prior therapy comprising one or more of a proteasome inhibitor, lenalidomide, pomalidomide, thalidomide, bortezomib, dexamethasone, cyclophosphamide, doxorubicin, carfilzomib, ixazomib, cisplatin, doxorubicin, etoposide, an anti-CD38 antibody, panobinostat, and elotuzumab.

### Claim 3

A method of treating a cancer that expresses BCMA in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of immune cells expressing a chimeric antigen receptor (CAR) directed to B Cell Maturation Antigen (BCMA), wherein the immune cells are administered in a dosage of from 150×106 cells to 450×106 cells, and wherein before said administration said subject has received one or more lines of prior therapy comprising one or more of a proteasome inhibitor, lenalidomide, pomalidomide, thalidomide, bortezomib, dexamethasone, cyclophosphamide, doxorubicin, carfilzomib, ixazomib, cisplatin, doxorubicin, etoposide, an anti-CD38 antibody, panobinostat, and elotuzumab.

### Claim 4 (depends on 3)

The method of claim 3, wherein said cancer that expresses BCMA is multiple myeloma, chronic lymphocytic leukemia, or a non-Hodgkins lymphoma (e.g., Burkitt's lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lymphoma).

### Claim 5 (depends on 1, 2, 3, 4)

The method of any of claims 1-4, wherein the subject has multiple myeloma that is high-risk multiple myeloma.

### Claim 6 (depends on 1, 2, 3, 4)

The method of any of claims 1-4, wherein the subject has multiple myeloma that is relapsed and refractory multiple myeloma.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any of claims 1-6, wherein before said administration said subject has received one or more lines of prior therapy comprising:
a. daratumumab, pomalidomide, and dexamethasone (DPd);
b. daratumumab, bortezomib, and dexamethasone (DVd);
c. ixazomib, lenalidomide, and dexamethasone (IRd);
d. daratumumab, lenalidomide and dexamethasone;
e. bortezomib, lenalidomide and dexamethasone (RVd);
f. bortezomib, cyclophosphamide and dexamethasone (BCd);
g. bortezomib, doxorubicin and dexamethasone;
h. carfilzomib, lenalidomide and dexamethasone (CRd);
i. bortezomib and dexamethasone;
j. bortezomib, thalidomide and dexamethasone;
k. lenalidomide and dexamethasone;
l. dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, etoposide and bortezomib (VTD-PACE);
m. lenalidomide and low-dose dexamethasone;
n. bortezomib, cyclophosphamide and dexamethasone;
o. carfilzomib and dexamethasone;
p. lenalidomide alone;
q. bortezomib alone;
r. daratumumab alone;
s. elotuzumab, lenalidomide, and dexamethasone;
t. elotuzumab, lenalidomide and dexamethasone;
u. bendamustine, bortezomib and dexamethasone;
v. bendamustine, lenalidomide, and dexamethasone;
w. pomalidomide and dexamethasone;
x. pomalidomide, bortezomib and dexamethasone;
y. pomalidomide, carfilzomib and dexamethasone;
z. bortezomib and liposomal doxorubicin;
aa. cyclophosphamide, lenalidomide, and dexamethasone;
bb. elotuzumab, bortezomib and dexamethasone;
cc. ixazomib and dexamethasone;
dd. panobinostat, bortezomib and dexamethasone;
ee. panobinostat and carfilzomib; or
ff. pomalidomide, cyclophosphamide and dexamethasone.

### Claim 8 (depends on 7)

The method of claim 7, wherein said subject has received two or more of said lines of prior therapy.

### Claim 9 (depends on 7)

The method of claim 7, wherein said subject has received three or more of said lines of prior therapy.

### Claim 10 (depends on 7)

The method of claim 7, wherein said subject has received four or more of said lines of prior therapy.

### Claim 11 (depends on 7)

The method of claim 7, wherein said subject has received five or more of said lines of prior therapy.

### Claim 12 (depends on 7)

The method of claim 7, wherein said subject has received six or more of said lines of prior therapy.

### Claim 13 (depends on 7)

The method of claim 7, wherein said subject has received seven or more of said lines of prior therapy.

### Claim 14 (depends on 7)

The method of claim 7, wherein said subject has received no more than three of said lines of prior therapy.

### Claim 15 (depends on 7)

The method of claim 7, wherein said subject has received no more than two of said lines of prior therapy.

### Claim 16 (depends on 7)

The method of claim 7, wherein said subject has received no more than one of said lines of prior therapy.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any of claims 1-16, wherein said subject exhibits at the time of said administration:
a. serum M-protein levels (serum protein electrophoresis [sPEP]) greater than or equal to about 0.5 g/dL or urine M-protein levels (urine protein electrophoresis [uPEP]) greater than or equal to about 200 mg/24 hours, and/or
b. light chain multiple myeloma (MM) without measurable disease in the serum or urine, with serum immunoglobulin free light chain greater than or equal to about 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio; and/or
c. Eastern Cooperative Oncology Group (ECOG) performance status of about 1 or less.

### Claim 18 (depends on 17)

The method of claim 17, wherein said subject additionally:
a. Has received at least three of said lines of prior treatment, including prior treatment with a proteasome inhibitor, an immunomodulatory agent (lenalidomide or pomalidomide) and an anti-CD38 antibody;
b. has undergone at least 2 consecutive cycles of treatment for each of said at least three lines of prior treatment, unless progressive disease (PD) was the best response to a line of treatment;
c. has evidence of progressive disease (PD) on or within 60 days of the most recent line of prior treatment; and/or
d. has achieved a response (minimal response or better) to at least one of said prior lines of treatment.

### Claim 19 (depends on 17)

The method of claim 17, wherein said subject additionally:
a. received only one prior anti-myeloma treatment regimen; and/or
b. has the following high risk factors: R-ISS stage III and early relapse, wherein the early relapse is defined as (i) if the subject has undergone induction plus a stem cell transplant, progressive disease less than 12 months since date of first transplant; or (ii) if the subject has received only induction, progressive disease (PD) less than 12 months since date of last treatment regimen which must contain at minimum, a proteasome inhibitor, an immunomodulatory agent and dexamethasone.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any of claims 1-19, wherein said subject shows progression-free survival of at least six months after said administration.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any of claims 1-19, wherein said subject shows progression-free survival of at least twelve months after said administration.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any of claims 1-21, wherein said chimeric antigen receptor comprises an antibody or antibody fragment that targets BCMA.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any of claims 1-22, wherein said chimeric antigen receptor comprises a single chain Fv antibody fragment (scFv).

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any of claims 1-22, wherein said chimeric antigen receptor comprises a BCMA02 scFv.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any of claims 1-22, wherein said immune cells are bb2121 cells.
